IECM
AXDX

Intrinsic Edge Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Intrinsic Edge Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-24,000
Closed -$5.49M – 148
2019
Q2 		$5.49M Hold
24,000
– – 0.65% 54
2019
Q1 		$5.04M Buy
24,000
+4,000
+20% +$750K 0.85% 40
2018
Q4 		$2.3M Buy
20,000
+10,576
+112% +$1.57M 0.39% 61
2018
Q3 		$2.16M Buy
9,424
+1,424
+18% +$315K 0.35% 92
2018
Q2 		$1.78M Buy
8,000
+5,000
+167% +$1.12M 0.21% 108
2018
Q1 		$686K Hold
3,000
– – 0.1% 121
2017
Q4 		$786K Sell
3,000
-7,208
-71% -$1.69M 0.14% 101
2017
Q3 		$2.29M Buy
10,208
+4,000
+64% +$982K 0.45% 56
2017
Q2 		$1.7M Buy
6,208
+4,000
+181% +$1.08M 0.52% 71
2017
Q1 		$534K Sell
2,208
-3,518
-61% -$804K 0.16% 106
2016
Q4 		$1.19M Buy
+5,726
New +$1.36M 0.51% 69

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Intrinsic Edge Capital Management's AXDX Position: Q3 2019 in Review

Intrinsic Edge Capital Management sold out of Accelerate Diagnostics (AXDX) in Q3 2019, closing a stake of 24,000 shares — an estimated $5.49M sold.

Intrinsic Edge Capital Management first reported a position in AXDX in Q4 2016 and held it in 11 quarters. The position peaked at $5.49M in Q2 2019. 113 funds tracked by Wall St. Rank hold AXDX as of Q3 2019.

  • Intrinsic Edge Capital Management reported no remaining Accelerate Diagnostics position as of Q3 2019 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 24,000 Accelerate Diagnostics shares in Q3 2019, an estimated $5.49M.
  • Intrinsic Edge Capital Management first reported a position in Accelerate Diagnostics in Q4 2016 and held it in 11 quarters.
  • Intrinsic Edge Capital Management's Accelerate Diagnostics position peaked at $5.49M in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2019.

Based on Intrinsic Edge Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.